


## BRCAPRO model underestimates BRCA1/2 mutation risk

21 March 2014



(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline *BRCA1/BRCA2* mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study published online March 17 in the *Journal of Clinical Oncology*.

Molly S. Daniels, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues calculated BRCAPRO scores for 589 patients with <u>ovarian cancer</u> referred for <u>genetic counseling</u> at three institutions. The BRCAPRO predictions were compared with observed mutations.

The researchers found that 31 percent of patients with ovarian cancer tested positive for *BRCA1* or *BRCA2* mutation. More mutations were observed than expected with BRCAPRO scores

APA citation: BRCAPRO model underestimates BRCA1/2 mutation risk (2014, March 21) retrieved 1 June 2021 from <a href="https://medicalxpress.com/news/2014-03-brcapro-underestimates-brca12-mutation.html">https://medicalxpress.com/news/2014-03-brcapro-underestimates-brca12-mutation.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

1/1